Inactive Instrument

NicOx SA Share Price Euronext Paris

NCOX

FR0000074130

News in other languages: NicOx SA

01/07	Bourse : Schneider se renforce dans l'IA, Air Liquide investit pour SK Hynix, Nike déçoit
01/07	Nicox dépose une demande d'autorisation de mise sur le marché aux Etats-Unis
01/07	La Bourse s'habitue à tout
01/07	Nicox : Demande d’autorisation de mise sur le marché de NCX 470 soumise aux Etats-Unis par Kowa, avec un paiement d’étape de 3 millions d’euros associé
23/06	Bourse : Sanofi enchaîne les AMM, Prysmian enchaîne les contrats, l'IA enchaîne les dépenses

More news

Managers and Directors: NicOx SA

Manager	Title	Age	Since
Gavin Spencer CEO	Chief Executive Officer	55	28/02/2024
Sandrine Gestin DFI	Director of Finance/CFO	58	01/01/2015
Doug Hubatsch CTO	Chief Tech/Sci/R&D Officer	-	13/12/2021

Director	Title	Age	Since
Gavin Spencer BRD	Director/Board Member	55	08/04/2024
Damian Marron CHM	Chairman	64	16/07/2024
Marc Bozec BRD	Director/Board Member	-	16/07/2024

More insiders

Specialty & Advanced Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NICOX SA	-7.95%	-9.39%	-	-	3.92Cr
MERCK & CO., INC.	-2.05%	-2.66%	+59.38%	+20.38%	32TCr
MERCK KGAA	-0.49%	+0.49%	+31.65%	-13.19%	7.16TCr
HALOZYME THERAPEUTICS, INC.	+0.02%	+1.36%	+37.67%	+96.18%	979.03Cr
KYOWA KIRIN CO., LTD.	-1.53%	-3.92%	-2.67%	-7.72%	839.15Cr
SK BIOPHARMACEUTICALS CO., LTD.	-0.76%	-2.73%	-16.42%	-13.85%	430.43Cr
YUHAN CORPORATION	+0.14%	-1.74%	-34.69%	+6.15%	381.41Cr
BETTA PHARMACEUTICALS CO., LTD.	-2.35%	-3.72%	-14.99%	+13.09%	358.15Cr
SUPERNUS PHARMACEUTICALS, INC.	+5.46%	+3.43%	+31.15%	+52.56%	259.03Cr
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+0.47%	+10.40%	+0.22%	-2.76%	224.72Cr
Average	-0.53%	+0.44%	+10.14%	+16.76%	4.75TCr
Weighted average by Cap.	-1.62%	-0.03%	+50.32%	+15.49%

See all sector performances

Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is bimatoprost grenod (NCX 470), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox SA generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the United States, and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.

Employees

Sector

Pharmaceuticals

More about the company

Rankings

Rankings

Currency / Forex

Commodities

Cryptocurrencies

Interest Rates

The best tools reserved for subscribers to boost the performance of your investments!

Market Cap	3.41Cr 3.92Cr 3.18Cr 2.92Cr 5.5Cr 373.57Cr 5.6Cr 37Cr 15Cr 186.29Cr 15Cr 14Cr 614.46Cr	P/E 2026 *	-5.52x	P/E 2027 *	38.7x
Enterprise Value	3.41Cr 3.92Cr 3.18Cr 2.92Cr 5.5Cr 373.57Cr 5.6Cr 37Cr 15Cr 186.29Cr 15Cr 14Cr 614.46Cr	EV / Sales 2026 *	11.4x	EV / Sales 2027 *	3.41x
Free-Float	99.65%	Yield 2026 *	-	Yield 2027 *	-

01/07	Nicox Submits NCX 470 New Drug Application In The United States	CI
01/07	Nicox files U.S. marketing approval application
23/06	Nicox Bags EUR6 Million Shareholder Loan	MT
23/06	Nicox Secures Backing From a Shareholder and Financial Partner
18/06	Nicox Receives Positive Feedback from China
18/06	Nicox Announces Positive Pre-Submission Regulatory Feedback in China Supporting NDA Filing for NCX 470	CI
30/04	Nicox S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
24/02	Nicox SA Highlights Positive NCX 470 Phase 3 Data Confirming Therapeutic Profile at the 2026 American Glaucoma Society Annual Meeting	CI
24/02	Edenred, Forvia, Freelance.com... Key Stocks to Watch Today in Paris -
24/02	Nicox Reports Positive Phase 3 Results for NCX 470
16/02	Nicox, Sanofi, Valneva... Stocks to Watch Today in Paris
16/02	Nicox Moves Forward with U.S. Health Authorities for Its NCX 470
05/01	Nicox Strengthens Its Financial Position

01/07	Nicox’s NCX 470 New Drug Application Submitted in the United States by Kowa, with Associated €3 million Milestone Payment	GL
23/06	Nicox and Vester Finance Sign Shareholder Loan Agreement to Support Strategic Activities for the Company	GL
18/06	Nicox Announces Positive Pre-submission Regulatory Feedback in China Supporting NDA filing for NCX 470	GL
08/06	Reminder: Nicox June 2024 Warrants will expire June 19, 2026	GL
03/06	Nicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting on June 24, 2026 and appointment of an ad hoc representative	GL

	2026 *	2027 *
Net sales	30L 34.52L 28.01L 25.71L 48.48L 33Cr 49.33L 3.3Cr 1.29Cr 16Cr 1.3Cr 1.27Cr 54Cr	1Cr 1.15Cr 93.36L 85.71L 1.62Cr 109.67Cr 1.64Cr 11Cr 4.31Cr 55Cr 4.32Cr 4.23Cr 180.39Cr
Net income	-60L -69.04L -56.02L -51.42L -96.96L -66Cr -98.65L -6.61Cr -2.59Cr -33Cr -2.59Cr -2.54Cr -108.24Cr	10L 11.51L 9L 9L 16.16L 11Cr 16.44L 1.1Cr 43.11L 5.47Cr 43.22L 42.26L 18Cr
Net Debt	-	-

NicOx SA Share Price Euronext Paris

Stocks

NCOX

FR0000074130

Pharmaceuticals

Valuation: NicOx SA

Latest news : NicOx SA

Press Releases: NicOx SA

News in other languages: NicOx SA

Quotes and Performance

Managers and Directors: NicOx SA

Specialty & Advanced Pharmaceuticals

Financials

Company Profile